RPL7P13

Across TCGA pan-cancer cohorts, RPL7P13 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated RPL7P13 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RPL7P13 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL7P13 expression acts as an unfavorable survival marker, although some lineages such as SKCM and THYM show a favorable association.

LIHC, UVM, and SKCM are the cancer types where RPL7P13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	III,IV	0.369	0.645	<.001	86	view →
UVM	DFS	Tertile	III,IV	0.172	0.907	<.001	45	view →
SKCM	DFS	Median	All	0.731	0.543	<.001	40	view →
THYM	OS	Quartile	II,III,IV	1.000	0.602	.003	30	view →
OV	OS	Quartile	II,III,IV	0.641	0.745	.009	30	view →
COAD	OS	Tertile	All	0.925	0.820	.005	25	view →
PAAD	DFS	Median	III,IV	0.370	0.853	.010	19	view →
THCA	DFS	Median	All	0.894	0.781	.004	17	view →
MESO	DFS	Median	III,IV	0.667	0.234	.004	15	view →
TGCT	DFS	Tertile	All	0.931	0.728	.002	12	view →
LAML	DFS	Median	All	0.724	0.411	.001	12	view →
LUAD	DFS	Tertile	IV	0.856	0.263	.011	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

RPL7P13–LIHC (OS)

Open the LIHC breakdown →